MSCs engineered to release IL7 and IL12 as “of-the-shelf cell therapy additives” will help to establish a pro-inflammatory response that prolongs the T cell anti-tumor attack and successfully counteracts repression through the tumor environment. This evidence concerns the gene IL7 and neoplasm.